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ABSTRACT
Introduction: The present study aimed to
evaluate clinical outcomes and costs associated
with timely versus delayed use of tumor
necrosis factor inhibitors (TNFis) among
patients with moderately to severely active
psoriatic arthritis (PsA) with and without
moderate/severe psoriasis (Ps) from a US
payer’s perspective.
Methods: An economic model evaluated PsA
patients initially treated with a TNFi (timely
TNFi use) or apremilast (delayed TNFi use).
Patients without joint (American College of
Rheumatology 20%, [ACR20]) improvement
either switched TNFis or initiated one. ACR20
responses were evaluated for all patients and
skin responses by Psoriasis Area Severity Index
75% (PASI75) for those with concomitant PsA
and Ps. Published randomized controlled trials
and publicly available databases provided
model inputs. Effectiveness measures included
1-year responses and number needed to treat
(NNT). Direct costs, costs per responder, and
incremental costs per responder were
calculated.
Results: After 1 year, timely TNFi-treated
patients had higher ACR20 responses (70.4%
vs. 59.6%) and lower NNTs (1.42 vs. 1.68)
compared with delayed use. Among PsA ? Ps
patients, timely TNFi use was associated with
higher ACR20 ? PASI75 responses (41.0% vs.
30.0%) and lower NNTs (2.44 vs. 3.33). Cost per
ACR20 responder was higher ($56,492 vs.
$52,835) among PsA patients without Ps; with
concomitant Ps, cost per ACR20 ? PASI75
responder was lower for timely TNFi use
($100,954 vs. $111,686). Incremental costs per
responder for timely versus delayed TNFi were
$76,823 in PsA and $71,791 in PsA and Ps.
Conclusion: Timely use of TNFis is a
cost-effective strategy for the management of
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INTRODUCTION
Psoriasis (Ps) affects an estimated 7.4 million
adults (3.2% of the total population) in the US
[1]. Nearly one in three psoriasis patients will
develop psoriatic arthritis (PsA) [2, 3], a chronic
inflammatory arthropathy typically associated
with Ps of the skin or nails and includes other
manifestations such as enthesitis, dactylitis,
uveitis, and spondylitis [4]. Given the
progressive nature of the disease, nearly half of
PsA patients will develop irreversible bone
erosions/joint destruction [5], leading to
impaired physical function [6], higher
likelihood of presenteeism and work disability
[7–9], and, consequently, high direct and
indirect costs [10–12]. Several treatment
options are available to manage symptoms and
inhibit structural disease progression. The
recently published Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) treatment recommendations (2016)
strongly recommend disease-modifying
anti-rheumatic drugs (DMARDs), including
methotrexate (MTX), leflunomide, sulfasalazine
and tumor necrosis factor inhibitors (TNFis) as
initial treatment for patients with PsA [13]. For
patients who fail to respond to DMARDs,
biologics (TNFis, interleukin [IL] 12/23 or IL 17
inhibitors) or a phosphodiesterase-4 inhibitor
(PDE4i) are suggested [13].
Recently, apremilast, a PDE4i, was approved
for treatment of active PsA [14] based on
demonstrated improvement in the signs and
symptoms of active PsA relative to placebo in
several randomized controlled trials (RCTs) that
did not evaluate structural joint damage
[15–19]. While there are no head-to-head RCTs
comparing the efficacy of apremilast versus a
TNFi, treatment responses were substantially
lower in individual recent Phase III RCTs with
apremilast [16, 20] than with TNFis in patients
with moderately to severely active PsA [21, 22],
despite generally similar inclusion criteria. By
week 16 in phase III RCTs (PALACE 1–3;
NCT01172938, NCT01212757, NCT01212770),
30–41% of apremilast-treated DMARD
incomplete responders (DMARD-IR) achieved
American College of Rheumatology 20%
responses (ACR20) [16–19], and 21–22%
patients achieved Psoriasis Area Severity Index
75 (PASI75) responses (PALACE-3;
NCT01212770) [18]. In contrast, 58–68% of
DMARD-IR patients treated with TNFis
achieved ACR20 and 51–59% PASI75
responses in 12–16 weeks [21, 22].
Additionally, an indirect comparison of RCT
data found that apremilast has similar efficacy
to MTX in treating a MTX-naı¨ve population
[23].
Both TNFis and the PDE4i have been
recommended by GRAPPA as treatment
options after initial DMARD failure. However,
it is not clear whether using apremilast or a
TNFi first may have different clinical and/or
economic impacts on patient outcomes. Use of
apremilast after DMARD failure may result in a
delay in prescribing TNFis known to reduce
structural progression. The current study was
designed to robustly model the economic
impact of timely versus delayed use of TNFis
in patients with moderately to severely active
PsA with/without moderate/severe Ps from a US
payer’s perspective.
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METHODS
Model Overview
This economic evaluation was performed using a
Markov state transition model to simulate costs
and outcomes over a 1-year time horizon in
patients with moderately to severely active PsA
(defined as presenting with C3 swollen and
C3 tender joints). Two treatment sequences were
compared: timely use of TNFi (initiating treatment
with adalimumab, etanercept, infliximab, or
golimumab; insufficient data were available for
certolizumab pegol) versus delayed use (initiating
treatment with apremilast), followed by a TNFi in
non-responders or those who lost responses.
The model structure (Fig. 1) builds on the
probabilistic decision-analytic models used in
the Health Technology Assessment of TNFis
(York Model), with some adaptations that
incorporate the impact of timely versus
delayed TNFi use [24]. The length of each
Markov cycle was 3 months (i.e., 13 weeks, not
including week 0), consistent with labeling
recommendations to assess treatment
responses at 12–16 weeks and with the British
Society of Rheumatology guidelines [25]. The
current model was built from a US third-party
payer’s perspective. Direct costs, including
treatment-related and other medical costs,
were calculated for each treatment sequence
based on Health Assessment Questionnaire
Fig. 1 Model structure. ACR20 American College of Rheumatology 20% response; PsA psoriatic arthritis; TNFi Tumor
Necrosis Factor inhibitors
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(HAQ) or PASI scores. In addition, the analysis
was conducted in the subpopulation with
concomitant moderate-to-severe Ps, defined as
having C3% body surface area involvement.
Model Parameters
Treatment Effectiveness
First-Line Effectiveness Patient characteristics
at treatment initiation were based on the
population enrolled in the Adalimumab
Effectiveness in Psoriatic Arthritis Trial
(ADEPT; NCT00195689) (Table 1) [26, 27].
Treatment responses were defined as ACR20
responses at month 3 (first cycle), the primary
outcome in most PsA RCTs [28]. For first-line
mixed TNFis, efficacy data by ACR20, ACR50,
and ACR70 responses (i.e. by achieving ACR 20,
50, and 70% responses) in the intention-to-treat
(ITT) population were pooled from Phase III
RCTs, weighted by each TNFi market share
(Table 2) [29]. The efficacy of apremilast 30 mg
twice daily in the per-protocol population of
Phase III RCTs (i.e., PALACE 1–3) was pooled
and weighted by the sample size in each trial.
Approximately 20% of patients in these trials
had previously received TNFis, while all patients
in ADEPT; NCT00195689 were biologic-naive
[30]. Because limited information was available
regarding efficacy in a biologic-naı¨ve
population, the base case model was
conducted based on the efficacy noted in all
patients in PALACE 1–3, and sensitivity analyses
were conducted using ACR20 responses among
biologic-naı¨ve patients reported in PALACE 1 [16]
and 3 [20].
Clinical efficacy at month 3 was then
translated into improvements in HAQ scores
relative to baseline (Table 2). This HAQ
calculation was developed using patient-level
data from the ADEPT trial, reported in the
adalimumab manufacturer submission to the
National Institute for Health and Care
Excellence (NICE) in the UK [31]. Initial HAQ
improvement was conditional on the level of
ACR responses achieved (i.e., ACR20, 50, 70)
and patient’s age, gender, HAQ score, MTX use,
and PsA duration at baseline. The algorithm
calculated HAQ changes for treatment
responders as weighted averages of ACR20, 50
and 70 as well as non-responders. In patients
with ACR20 responses at month 3, average
decreases in HAQ from baseline were 0.73 and
0.65 for TNFi and apremilast, respectively.
Responders were considered to have
maintained their initial improvement in HAQ
until they withdrew. Patients continued current
treatment after month 3 as long as they
maintained their initial joint response,
regardless of skin response, until
discontinuation. Non-responders were
assumed to have limited improvements in
joint disease at an average decrease in HAQ of
0.13 with both TNFis and apremilast at month
3. Non-responders moved to the next line of
therapy at the beginning of the second cycle.
Subsequent-Line Effectiveness In
non-responders or patients who lost ACR20




PsA duration, year 10
Baseline HAQ 1.3
Ps deﬁned as BSA involvement C3% 40%
Baseline PASI (patients with BSA C3%) 7.4
MTX use at baseline, % 51%
PsA psoriatic arthritis; HAQ Health Assessment
Questionnaire; Ps psoriasis; BSA body surface area; PASI
Psoriasis Area Severity Index; MTX methotrexate
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responses after 3 months, the model considered
subsequent treatment with a different TNFi
(timely use of TNFi arm) or initiation of a
TNFi (delayed use arm).
Responses for subsequent lines of
treatment in the timely use of TNFi arm
were assumed to be lower than first-line
responses, based on findings of lower efficacy
with a 2nd and 3rd TNFi in patients with
rheumatoid arthritis (RA) [32]. Reduction in
short-term responses were estimated as 25, 27
and 37% relative to first-line ACR20, ACR50
and ACR70 responses, respectively [32]. On
the other hand, there is no evidence regarding
the effectiveness of delayed TNFi use
following apremilast failure—a decrease in
efficacy was assumed. This was based on
observations from rescue treatment in the
ADEPT trial and its open-label 48-week
extension, which suggested that patients
who initially received TNFis experienced
better outcomes than those originally
randomized to receive placebo and then
received the TNFis [26, 27]. The efficacy of
TNFi after apremilast was assumed to decrease
by 21, 14 and 8% for ACR20, ACR50 and
ACR70 respectively, again based on the rescue
arm of the ADEPT RCT [26, 27].
Treatment Withdrawal Based on real-world
observations of treatment discontinuation and
switching, the model assumed a certain risk of
withdrawal from TNFi therapy after each cycle,
due to loss of efficacy, adverse events or other
reasons. Withdrawal rates for first and
subsequent line TNFi use were obtained from a
British registry study and assumed to be
constant over time (Table 2) [33]. As long-term
real-world withdrawal rates have not yet been
reported for apremilast, they were assumed to
be the same as for TNFis. When patients
withdrew from treatment, HAQ scores were
assumed to rebound to baseline levels and
patients were moved to the next line of
treatment at the beginning of the next cycle.
Outcomes for Symptomatic Care For patients
who failed a subsequent-line TNFi, the model
placed these patients in symptomatic care. This
was based on the York model [24], given that
treatment guidelines at the time of this analysis
did not have recommendations past second-line
treatment with TNFi biologics [25, 34, 35]. For
patients who failed TNFi treatment, the model
assumed that their HAQ score would continue
to deteriorate from the last value assigned on
subsequent-line treatment at a rate of 0.018 per
cycle—based on an assumption of inefficacy
with subsequent DMARD treatment for PsA
symptoms, as suggested by clinical expert
opinion [31].
Mortality Since PsA patients are known to
have an increased risk of death compared with
the general population [36], an additional
mortality risk of 65% for males and 59% for
females [36] was considered for PsA when
estimating mortality and the model assumed
no difference in mortality rates between
treatments.
Effectiveness in Treating Psoriasis TNFis are
approved to treat both joint and skin disease. A
subgroup analysis examined clinical
improvement, measured by 75% improvement
in PASI as well as ACR20 at each Markov cycle.
Effectiveness for both skin and joint
manifestations was modeled in this previously
defined subgroup. Since there is a positive
correlation between responses (e.g., ACR
responders are more likely to be PASI
responders [37–40]), a bivariate evidence
synthesis was performed. Correlations between
PASI75 and ACR20 responses were again derived
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Table 2 Effectiveness inputs
Description Timely TNFi use Delayed TNFi use
Initial treatment 1st TNFia Apremilast
Effectiveness at Month 3 among PsA patients
Probability of achieving ACR20 response 0.580 0.371
Probability of achieving ACR50 response 0.364 0.140
Probability of achieving ACR70 response 0.155 0.030
Effectiveness at Month 3 among the subgroup with Ps
Probability of achieving PASI50 response 0.630 0.419
Probability of achieving PASI75 response 0.438 0.220
Probability of achieving PASI90 response 0.260 0.110
Probability of achieving ACR20 ? PASI75 response 0.331 0.158
Effectiveness at Month 3 among biologic naı¨ve patients (sensitivity analyses)
Probability of achieving ACR20 response NA 0.435
Probability of achieving ACR50 response NA 0.171
Probability of achieving ACR70 response NA 0.044
Withdrawal rate per cycle after the ﬁrst cycle 0.023 0.023
Subsequent treatment 2nd TNFia 1st TNFia (delayed)
Effectiveness at Month 3 among PsA patients
Probability of achieving ACR20 response 0.435 0.458
Probability of achieving ACR50 response 0.266 0.314
Probability of achieving ACR70 response 0.096 0.143
Effectiveness at Month 3 among the subgroup with Ps
Probability of achieving PASI50 response 0.638 0.630
Probability of achieving PASI75 response 0.448 0.438
Probability of achieving PASI90 response 0.267 0.260
Probability of achieving ACR20 ? PASI75 responseb 0.271 0.277
Withdrawal rate per cycle after the ﬁrst cycle 0.073 0.073
Change in HAQ given an ACR20 response at month 3c
ACR20 responder -0.716 -0.747
ACR20 non-responder -0.130 -0.130
HAQ change per cycle while on symptomatic care 0.018 0.018
Standardized mortality rate for PsA vs. general population
Male 1.65 1.65
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from the ADEPT trial [26] and used to estimate
the probability a patient would have both joint
and skin responses (Table 2). This same
correlation was used across all treatment
groups, assuming the relationship between
joint and skin responses are independent of
the treatment patients received (as known for
TNFis) [24].
Costs
Based on a third-party payer’s perspectives, the
base case model considered only direct costs,
including treatment-related (product,
administration, and monitoring costs) and
other medical costs (Table 3).
Treatment-related costs were calculated for
TNFis based on market share [29], unit prices,
and dose per cycle of each therapy. Unit prices
for TNFis and apremilast were based on
wholesale acquisition costs obtained from
ReadyPrice (assessed April 2014) [41]. Dose per
cycle was calculated based on product label
recommended dosing schedules. Patients
receiving TNFis also incurred monitoring costs
[42] and patients receiving infliximab incurred
administration costs for intravenous infusions
administered by a healthcare professional. No
monitoring or administration costs were
assumed for apremilast. No treatment-related
costs were assumed for symptomatic care in the
base case model. Costs for using MTX were
tested in sensitivity analyses.
The model assumed that PsA patients
incurred other medical costs for inpatient and
outpatient visits and that costs would increase
with severity of arthritis and/or psoriasis [43].
Due to the lack of economic studies on medical
costs by HAQ in PsA, the health service costs of
treating arthritis were derived from a US-based
study that estimated the effect of HAQ on direct
costs in patients with RA [43]. The study
reported total direct costs corresponding to
quartiles of HAQ scores, with 75% attributed
to medical services. A weighted linear regression
was fitted using the mid-point of the HAQ score
as an independent variable and other medical
costs as the dependent variable, weighted by the
number of patients in each quartile. This
coefficient was estimated to be $1040, the
mean change in 3-month cost for a 1-unit
change in HAQ. Medical costs of treating PsA
were estimated as a function of HAQ score at
Table 2 continued
Description Timely TNFi use Delayed TNFi use
Female 1.59 1.59
ACR20, 50, 70 American College of Rheumatology 20, 50, and 70% response; HAQ Health Assessment Questionnaire;
PASI 50, 75, and 90 Psoriasis area severity index reduction of 50, 75, and 90%; PsA psoriatic arthritis; Ps psoriasis; TNFi
tumor necrosis factor inhibitor
a The treatment effectiveness for mixed TNFi biologics in ﬁrst and subsequent line were estimated based on the market
shares of biologic use in patients with PsA [29]. The proportions of ﬁrst-line biologics were estimated to be 37.0% for
adalimumab, 35.1% for etanercept, 22.4% for inﬂiximab, and 5.5% golimumab, while the shares for the subsequent line were
32.8, 32.8, 26.6, and 7.8%, respectively
b The probability of achieving PASI75 response in the ﬁrst cycle was modeled using a joint distribution with ACR20 using
Bayesian bivariate analysis
c PASI score and HAQ score changes in the ﬁrst cycle of treatment were estimated based on PASI (50/75/90) and ACR
(20/50/70) response rates. The maximum HAQ score was 3
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Table 3 Cost inputs
Description Cost per cycle (3 months)




Inﬂiximabb $17,660 for the ﬁrst cycle; $7406 after the ﬁrst cycle
Apremilast $5531 for the ﬁrst cycle; $5688 after the ﬁrst cycle
Monitoring costs







Medical costs related to Ps
PASI75 responder $22
PASI75 non-responder $1150
Indirect costs (modeled in the sensitivity analyses)c
HAQ\ 0.5 $2265
HAQ 0.5 to\1.1 $4111
HAQ 1.1 to\1.6 $6931
HAQ 1.6 to\2.1 $9992
HAQ 2.1 to\2.6 $13,639
HAQ C 2.6 $9141
TNFi Tumor necrosis factor inhibitor; HAQ Health Assessment Questionnaire; Ps psoriasis; PASI Psoriasis Area Severity
Index
a Treatment costs for mixed TNFi biologics in ﬁrst and subsequent line were estimated based on the market shares of
biologic use in patients with PsA [29]. The proportions of ﬁrst-line biologics were estimated to be 37.0% for adalimumab,
35.1% for etanercept, 22.4% for inﬂiximab, and 5.5% golimumab, while the shares for the subsequent line were 32.8, 32.8,
26.6, and 7.8%, respectively
b The drug and drug administration costs for inﬂiximab included costs for intravenous infusion administered by a
healthcare professional ($85.8 per infusion based on the CMS physician fee schedule 2014)
c Direct costs extracted from the source included inpatient costs, outpatient costs, drug costs and ancillary costs. Medical
costs were assumed to be 75% of the direct costs
d Linear interpolation was used to estimate the association between costs and HAQ score
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each cycle. For the subgroup of patients with
concomitant psoriasis at baseline, patients
achieving PASI75 responses were assumed to
receive phototherapy once a year. Those who
did not achieve PASI75 responses incurred
Ps-related medical costs [24], obtained from a
real-world claims study of Ps-associated
treatment costs [44].
All costs were inflated to 2014 United States
Dollar (USD). No discounting was applied to the
base case model, due to the short time horizon
of the analysis; 3% discounting rates for both
effectiveness and costs were considered when
varying time horizon to 5 years in the
sensitivity analyses.
Model Outputs
The base case model estimated total direct costs
and effectiveness for each treatment sequence
at 1 year after treatment initiation. Among
patients with PsA, effectiveness was measured
by joint responses (ACR20) and mean time as an
ACR20 responder at year 1. Among patients
with both joint and skin manifestations,
treatment effectiveness was measured by
combined ACR20 ? PASI75 responses and
mean time as ACR20 ? PASI75 responders.
Numbers needed to treat (NNT) for
achievement of ACR20 or ACR20 ? PASI75
responses were also reported.
Based on effectiveness and costs outputs,
costs per responder for each treatment sequence
were calculated. Incremental costs per
responder measured the costs per ACR20 (or
ACR20 ? PASI75) responders with timely vs.
delayed use of TNFi.
Sensitivity Analyses
One-way sensitivity analyses were conducted to
examine the impact of change in one key model
input or assumption, while holding others at
base case values. Model inputs that were varied
include treatment costs, other medical costs,
efficacy, treatment withdrawal rate, baseline
patient characteristics, mortality rate, and time
horizon. In addition, the societal perspective,
considering both direct and indirect costs, was
modeled in sensitivity analyses—indirect costs
were estimated as a function of HAQ, based on
the similar approach for medical costs. Since no
US studies were found to estimate indirect costs
associated with PsA, the number of working
days missed due to RA were obtained from a
German study [45] and the average wage per
day in the US [46] was applied to estimate total
indirect costs associated with given HAQ scores.
A detailed list of parameters and
corresponding ranges/assumptions of the
one-way sensitivity analyses are provided in
Fig. 2.
The model and sensitivity analyses were
conducted using Excel 2010 (Microsoft
Corporation, Redmond, WA).
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Base Case Analysis
After 1 year, patients with moderately to
severely active PsA who started a TNFi in a
timely manner had higher ACR20 responses
(70.4% vs. 59.6%), and corresponding lower
NNTs (1.42 vs. 1.68), than those first treated
with apremilast and later receiving a TNFi.
Mean times with responses were also longer
for timely vs. delayed use of TNFi (7.2 months
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vs. 5.8 months). Patients with timely TNFi
treatment incurred higher costs ($39,754 vs.
$31,513). The cost per ACR20 responder was
similar between the two treatment groups
($56,492 vs. $52,835, respectively) and the
1-year incremental cost per ACR20 responder
was $76,823 for timely vs delayed TNFi use
(Table 4a).
Among patients with concomitant moderate
to severe Ps, timely TNFi use was associated with
higher combined ACR20 ? PASI75 responses
(41.0% vs. 30.0%), corresponding to lower
NNTs (2.44 vs. 3.33), with longer durations of
response (4.2 months vs. 2.8 months). Timely
TNFi treatment was also associated with higher
costs during the 1st year ($41,437 vs. $33,510),
resulting in the incremental cost per
ACR20 ? PASI75 responder as $71,791 for
timely vs delayed use. However, cost per
ACR20 ? PASI75 responder was lower for
initial treatment with TNFi than apremilast
($100,954 vs. $111,686) (Table 4b).
One-Way Sensitivity Analyses
In the one-way sensitivity analyses, incremental
cost per ACR20 responder ranged from $51,274
to $116,624. Factors with the largest impact on
incremental costs were treatment-related costs,
apremilast ACR20 responses at 12 weeks, and a
longer time horizon (i.e., 5 years). Incremental
costs per ACR20 ? PASI75 responders ranged
from $51,760 to $91,822 and were most
sensitive to treatment-related costs, indirect
costs, and a longer time horizon (Fig. 2).
DISCUSSION
Recently, several new therapies have been
approved for PsA, prompting further
assessments of treatment options [47, 48] and
their cost-effectiveness [24, 49–51], as well as
issuance of new treatment recommendations
[13]. In patients with active PsA, TNFis have
proven highly effective in treating PsA
symptoms and inhibiting structural
progression [52–54]. A newly introduced
agent, apremilast, has been shown to be
effective in treating the signs and symptoms of
PsA. A few other studies have attempted to
investigate the economic impact of using
apremilast before or instead of TNFi treatment
and concluded that apremilast is a more
cost-effective option over a lifetime horizon
[55], with lower costs per responder relative to
TNFis in a one-year treatment model [56].
However, from the available published
information, these previously published
models did not consider concomitant Ps or
structural progression in PsA, and still produced
only modest cost savings with the use of
apremilast.
In the present economic model, patients
initially treated with a TNFi had higher
responses and lower NNTs than those initially
receiving apremilast. Although patients with
timely use of a TNFi had higher
treatment-related costs than the delayed use
group after 1 year, these costs were partially
offset by lower other medical costs. Based on
costs-per-responder estimates, total annual
costs for ACR20 responders were similar in
both groups, although slightly higher with
Fig. 2 Tornado diagram of one-way sensitivity analyses for
incremental costs per responder. Top panel patients with
PsA (Incremental cost per ACR20 responder). Bottom
panel Patients with PsA and psoriasis (Incremental cost per
ACR20 ? PASI75 responder). ACR American College of
Rheumatology; HAQ Health Assessment Questionnaire;
PsA psoriatic arthritis; PsO psoriasis; TNFi Tumor
Necrosis Factor inhibitors Alternative medical costs inputs
were obtained from Kobelt et al. 2002 [63]. The costs were
inﬂated to 2014 USD
b
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A. Patients with PsA
Costs
Direct costs $39,754 $31,513 $8241
Treatment-related costs $31,751 $22,904 $8847
Other medical costs $8003 $8609 -$606
Effectiveness
% of ACR20 responder 70.4% 59.6% 10.7%
Number needed to treata 1.42 1.68 9.32
Mean time with joint response (month) 7.2 5.8 1.4
Cost per responder
Cost per ACR20 responder $56,492 $52,835 $3657
Incremental cost per joint responder Arm A vs. Arm B
$76,823
B. Subgroup of patients with PsA and psoriasis
Costs
Direct costs $41,437 $33,510 $7927
Treatment-related costs $31,751 $22,904 $8847
Other medical costs $9686 $10,606 -$920
Effectiveness
% of ACR20 ? PASI75 responder 41.0% 30.0% 11.0%
Number needed to treata 2.44 3.33 9.06
Cost per responder
Cost per ACR20 ? PASI75 responder $100,954 $111,686 -$10,732
Incremental cost per joint and skin responder Arm A vs. Arm B
$71,791
ACR20 American College of Rheumatology 20% response; PASI Psoriasis Area Severity Index; PsA psoriatic arthritis; TNFi
Tumor Necrosis Factor inhibitors
a Number needed to treat is deﬁned as the average number of patients who need to be treated for one responder. The
comparison results (in italics) between the two arms should be interpreted as the number of patients who need to be treated
to observe one responder in arm A versus arm B
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timely use. When both joint and skin responses
were accounted for, responses and cost trends
were similar to analyses that were based on joint
responses only, but total costs were much lower
for timely use vs. delayed use of TNFis. These
results indicate that, overall, timely treatment
with TNFis is more expensive than delayed
treatment, but for those patients with both skin
and joint manifestations, cost savings can be
substantial. Since 46–83% patients enrolled in
TNFi RCTs [57] have manifestations of Ps, this
finding underscores the need to consider
effectiveness for both joint and skin disease
when assessing treatments for PsA.
This study provides important information
on economic and clinical outcomes associated
with choice of TNFis versus apremilast as 1st-line
treatment for moderately to severely active PsA,
with careful attention to presenting an accurate
model of the disease. Nonetheless, this still
remains a model, which cannot account for the
natural history of the disease or all aspects of its
treatment. Sensitivity analyses were performed
to identify largest areas of uncertainty [58] in the
model—indicating that, among other factors,
ACR20 responses with apremilast treatment and
1st-line withdrawal rates following apremilast
had a large impact on the model results. Due to
lack of available information, some assumptions
were necessary to incorporate into the model:
ACR20 responses were derived from RCTs with
apremilast that included mixed populations of
treatment-naı¨ve and TNFi-exposed patients.
Based on reported efficacy, it is possible that
treatment-naı¨ve patients receiving apremilast
might achieve higher responses than in the
mixed population trials—although ACR20 rates
at week 14 were 28–31% in the PALACE 4 trial
(NCT01307423) in DMARD (synthetic and
biologic)-naı¨ve patients [59], below those
observed in PALACE 1–3 (which were used in
the present analysis). Therefore, sensitivity
analyses were conducted to include a
compensatory factor for ACR20 responses with
apremilast, increasing response rates from the
observed 37% to an estimated 43%, based on the
subgroup analysis in biologic-naı¨ve patients, as
reported in PALACE 1 and 3. Furthermore, since
there is no information regarding the degree to
which the effectiveness of TNFis may be
impacted by prior use of apremilast, the model
used rescue data from RCTs to estimate the
difference between timely vs. delayed initiation
of a TNFi. Nonetheless, the effect of this latter
adjustment on the primary findings was not
substantial, and the model assumed the same
withdrawal rates for the two treatment
sequences, as there were no long-term
observational data with apremilast.
Despite these sensitivity analyses, several
limitations of the current model must be
acknowledged. The effectiveness mode inputs
were mainly based on RCTs, but patients
enrolled in trials differ from those treated in
routine clinical practice, and trial design may
impose additional treatment restrictions not
generally observed in clinical practice. Results
may therefore not be generalizable to the
greater PsA patient population.
There are no head-to-head trials comparing
the two modeled treatment sequences;
therefore, effectiveness data were obtained
from a mix of several RCTs and observational
studies, and the comparative results may be
biased by differences between populations and
study design. For example, while all RCTs for
TNFis included in the present study were based
on the ITT population, all RCTs for apremilast
were based on the per-protocol population. In
addition, RCTs with apremilast (PALACE 1–3
[16, 20, 60, 61]) included both TNFi-naı¨ve and
-experienced patients, and a subgroup analysis
of all modeled outcomes was not available for
TNFi-naı¨ve patients. The present analysis may
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have underestimated ACR20 responses in
TNFi-naı¨ve patients, which could have biased
results against initial use of apremilast. On the
other hand, as there are no data that apremilast
can inhibit the progression of structural
damage, the current analysis may be
conservative relative the cost-efficacy of
apremilast vs a TNFi.
The model included several assumptions
regarding the effectiveness of 1st versus 2nd-line
TNFi use, and early vs. delayed treatment; these
assumptionswere tested in sensitivity analyses and
the model was not sensitive to the assumption of
decreased efficacy with prior exposure. While
sequential use of TNFis is common in clinical
practice, the model assumes that patients receive
no treatment (i.e., symptomatic care) after
subsequent TNFi therapy—as assumed by other
models of PsA treatment [24]. However, the newly
published GRAPPA recommendations suggest
possible rescue of response with IL-12/23 or IL-17
inhibitors and PDE4i in patients who have TNFi
failure [13]. At the timeofmodel development, the
IL-17 inhibitors had not yet been approved for this
indication and their clinical evidence after two
TNFis or one TNFi and one PDE4i failure are
lacking. Therefore, the current model did not
consider these treatment options after
subsequent TNFi failure.
Finally, uncertainty [62] remains regarding
progression of HAQ scores with and without
TNFi and apremilast treatment and their
short-term effectiveness in PsA. Further research
is needed on these topics, as all current
cost-effectiveness models of treatment for PsA
rely on assumptions for these inputs [24].
CONCLUSION
Timely use of TNFis is a cost-effective strategy
for management of moderately to severely
active PsA, due to greater improvements in
joint and skin manifestations than observed
with delayed initiation of TNFis. Furthermore,
timely use of TNFis can reduce medical costs,
which can partially offset the higher
treatment-related costs compared with delayed
TNFi treatment. Future research on the impact
of delayed use of TNFis on patients’
health-related quality of life is warranted.
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